Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Court Considers Cipla Challenge To Roche Tarceva Patent

This article was originally published in PharmAsia News

Executive Summary

The Delhi high court is considering a Roche Scientific injunction seeking to halt Cipla's marketing of a generic version of Roche's Tarceva (erlotinib hydrochloride) drug for treating lung cancer. Genentech and OSI Pharmaceuticals, co-developers of the drug, issued a global license to Roche, which obtained the India patent. Besides Cipla, Lawyers Collective, a non-government organization based in Mumbai, was considered another candidate to challenge the Indian patent. Roche India's managing director said marketing a generic would infringe the company's patent. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts